Kitonail (Ciclopirox)

Ciclopirox acts by chelating polyvalent cations, which interferes with fungal sterol synthesis. This disruption impairs membrane transport and essential cellular functions, ultimately inhibiting fungal growth and leading to the clearance of the infection at the site of application.

The dosing regimen for Kitonail is determined by the prescribing healthcare professional based on the severity and location of the infection. The prescriber will specify the amount to apply, frequency, and duration of treatment.

Safety data for ciclopirox in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To request Kitonail, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Compared with oral antifungals, Kitonail offers a topical option that avoids systemic exposure and related side effects. While oral agents may provide faster systemic clearance, ciclopirox nail lacquer delivers high local concentrations directly to the infected nail, which can be advantageous for localized infections.

Kitonail should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and efficacy.

Kitonail is applied topically to the affected nail or skin area. The prescriber will advise the specific amount to use, typically a thin layer, and the frequency (often once daily). The nail surface should be clean and dry before application.

Serious risks, though rare, include severe allergic reactions such as allergic contact dermatitis, systemic hypersensitivity, and, in extremely rare cases, severe skin reactions like Stevens‑Johnson syndrome. Patients should discontinue use and seek medical attention if they experience widespread rash, swelling, or systemic symptoms.

Kitonail should not be used by individuals with known hypersensitivity to ciclopirox or any component of the formulation. It is also contraindicated on broken skin or extensive skin lesions, and caution is advised for pregnant or breastfeeding women unless deemed necessary by a healthcare professional.